Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC + Pembrolizumab in Advanced Melanoma
NCT02263508Phase 3Terminated
- Sponsor
- Amgen
- Start
- Dec 2014
- Primary completion
- Mar 2021
- Modality
- Oncolytic Viruses
- Countries
- 21
01
Overview
A Phase 3 trial of talimogene laherparepvec in melanoma, sponsored by Amgen. Started Dec 2014; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02263508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263508.